Requests that the FDA determine whether the Reference Listed Drug (RLD) LASIX ORAL SOLUTION, 10 mg/mL; New Drug Application (NDA) 017688 of SANOFI AVENTIS US LLC has been voluntarily withdrawn from sale for safety or efficacy reasons. | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-4567

Requests that the FDA determine whether the Reference Listed Drug (RLD) LASIX ORAL SOLUTION, 10 mg/mL; New Drug Application (NDA) 017688 of SANOFI AVENTIS US LLC has been voluntarily withdrawn from sale for safety or efficacy reasons.

Documents

Comments

Key Dates

Comment Period OpensApr 24, 2026

Documents

Type	Title	Posted	Comments	Status
Other	Acknowledgement Letter from FDA DMB to Lachman Consultant Services, Inc.	Apr 24, 2026	--

Keywords

CDER

Citizen Petition

Lachman Consultant Services Inc

determine whether the Reference Listed Drug

LASIX ORAL SOLUTION

10 mg mL

New Drug Application 017688

of SANOFI AVENTIS US LLC

Data from Regulations.gov